Home › Blood Cancers › NCT06579469

Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy

Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy (PROSPER)

Who can join

Up to age 30 · All sexes

Inclusion Criteria:

* Participants must have received an initial systemically-administered CAR T cell infusion within the last 1-3 months (+/- 14 days).

  * Initial infusion is defined as the first administration of a CAR T cell product the participant has not previously received OR receipt of a CAR T cell product previously received after an interval allogeneic HSCT.
* Age ≤ 30 years at CAR T cell infusion.

Exclusion Criteria:

* Active malignancy other than the disease under study.
* Planned consolidative HSCT within 3 months post CAR T cell infusion.
* Received or planned additional disease directed therapy post CAR T cell infusion.
* Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.

About the study

This study is being done to learn more about the short-term and long-term side effects of CAR-T cell therapy. Specifically, researchers want to know how often patients get infections, have delays in recovering blood cell counts and/or have damage to the nervous system.

Sponsor: St. Jude Children's Research Hospital · Participants: 100 · Started: Jan 20, 2026

Contact the study team

• Rebecca Epperly, MD · Phone: 888-226-4343

Official record on ClinicalTrials.gov — NCT06579469

Locations in the U.S.

Conditions

• Blood Cancers

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.